Eccentric hypertrophy impairs outcome after TAVR.

IF 3.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
R Thalmann, V Obermeier, Dominik S Westphal, I Diebold, T Trenkwalder, C Pellegrini, G Buglio, H Seoudy, P Hoppmann, C Bradaric, U Schön, E Holinski-Feder, N Lettmann, H Ruge, M Erlebach, C Fuetterer, K L Laugwitz, M Krane, D Frank, C Kupatt
{"title":"Eccentric hypertrophy impairs outcome after TAVR.","authors":"R Thalmann, V Obermeier, Dominik S Westphal, I Diebold, T Trenkwalder, C Pellegrini, G Buglio, H Seoudy, P Hoppmann, C Bradaric, U Schön, E Holinski-Feder, N Lettmann, H Ruge, M Erlebach, C Fuetterer, K L Laugwitz, M Krane, D Frank, C Kupatt","doi":"10.1007/s00392-024-02582-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Aortic stenosis (AS) induces cardiac remodeling upon chronic left ventricular (LV) pressure overload. Here, we analyzed the clinical outcome of patients undergoing transcatheter aortic valve replacement (TAVR) for symptomatic AS with regard to varying LV hypertrophy patterns. Moreover, we investigated the genetic influence on development of different hypertrophy patterns, measured by polygenic risk scores (PRS).</p><p><strong>Methods: </strong>1703 patients with severe AS undergoing TAVR were categorized according to LV mass index and relative wall thickness in four subgroups: normal geometry (NG, n = 57), concentric remodeling (CR; n = 388), concentric hypertrophy (CH; n = 993) and eccentric hypertrophy (EH; n = 265). Data was analyzed retrospectively with regard to clinical outcome. In a substudy, 520 patients affected by CH (n = 237), EH (n = 139) or CR (n = 164) were analyzed using two PRS that have been previously associated with hypertrophic and dilated cardiomyopathy.</p><p><strong>Results: </strong>1 year after TAVR, for EH, in contrast to the remaining groups (NG, CR, CH), a significant difference in all-cause mortality was observable (mortality 17.4% EH, 14.0% NG, 12.4% CR, 14.0% CH, p = 0.001). This difference was observed up to 4 years (mortality 41.9% EH, 26.9% CH, 28.1% CR, 26.4% NG, p = 0.001). Of note, higher percentiles in a PRS for hypertrophic cardiomyopathy were associated with a reduced likelihood of EH in patients with AS (p = 0.046).</p><p><strong>Conclusions: </strong>The EH group had a statistically significant poorer 1-year and 5-year outcomes than the other groups. PRS might help predict myocardial reactions in patients with aortic stenosis in future.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-024-02582-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Aortic stenosis (AS) induces cardiac remodeling upon chronic left ventricular (LV) pressure overload. Here, we analyzed the clinical outcome of patients undergoing transcatheter aortic valve replacement (TAVR) for symptomatic AS with regard to varying LV hypertrophy patterns. Moreover, we investigated the genetic influence on development of different hypertrophy patterns, measured by polygenic risk scores (PRS).

Methods: 1703 patients with severe AS undergoing TAVR were categorized according to LV mass index and relative wall thickness in four subgroups: normal geometry (NG, n = 57), concentric remodeling (CR; n = 388), concentric hypertrophy (CH; n = 993) and eccentric hypertrophy (EH; n = 265). Data was analyzed retrospectively with regard to clinical outcome. In a substudy, 520 patients affected by CH (n = 237), EH (n = 139) or CR (n = 164) were analyzed using two PRS that have been previously associated with hypertrophic and dilated cardiomyopathy.

Results: 1 year after TAVR, for EH, in contrast to the remaining groups (NG, CR, CH), a significant difference in all-cause mortality was observable (mortality 17.4% EH, 14.0% NG, 12.4% CR, 14.0% CH, p = 0.001). This difference was observed up to 4 years (mortality 41.9% EH, 26.9% CH, 28.1% CR, 26.4% NG, p = 0.001). Of note, higher percentiles in a PRS for hypertrophic cardiomyopathy were associated with a reduced likelihood of EH in patients with AS (p = 0.046).

Conclusions: The EH group had a statistically significant poorer 1-year and 5-year outcomes than the other groups. PRS might help predict myocardial reactions in patients with aortic stenosis in future.

偏心肥厚损害TAVR后的预后。
背景:主动脉瓣狭窄(AS)在慢性左心室(LV)压力过载时引起心脏重构。在这里,我们分析了经导管主动脉瓣置换术(TAVR)治疗不同左室肥厚模式的症状性AS患者的临床结果。此外,我们通过多基因风险评分(PRS)研究了遗传对不同肥厚模式发展的影响。方法:1703例重度AS行TAVR的患者根据左室质量指数和相对壁厚分为4个亚组:正常几何(NG, n = 57)、同心重构(CR;n = 388),同心圆肥大(CH;n = 993)和偏心肥厚(EH;n = 265)。回顾性分析有关临床结果的数据。在一项亚研究中,520例受CH (n = 237)、EH (n = 139)或CR (n = 164)影响的患者使用两种先前与肥厚和扩张性心肌病相关的PRS进行分析。结果:TAVR后1年,EH组与其他组(NG、CR、CH)相比,全因死亡率有显著差异(EH组死亡率17.4%,NG组死亡率14.0%,CR组死亡率12.4%,CH组死亡率14.0%,p = 0.001)。这种差异持续到4年(EH死亡率41.9%,CH死亡率26.9%,CR死亡率28.1%,NG死亡率26.4%,p = 0.001)。值得注意的是,肥厚性心肌病的PRS中较高的百分位数与AS患者EH的可能性降低相关(p = 0.046)。结论:EH组1年和5年预后较其他组差,具有统计学意义。PRS可能有助于预测未来主动脉瓣狭窄患者的心肌反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Research in Cardiology
Clinical Research in Cardiology 医学-心血管系统
CiteScore
11.40
自引率
4.00%
发文量
140
审稿时长
4-8 weeks
期刊介绍: Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery. As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信